Fig. 6.

Overview of the functional and genetic cancer patient stratification and disease diagnosis approach using microfluidics. Tumor biopsies can be used to determine first line of treatment strategy based on their genetic and phenotypic data. The droplet-based microfluidic technology can be used to isolate CTCs from patients to monitor the disease state. The mass accumulation rate can be monitored through a series of suspended microchannel resonators to allow drug susceptibilities of patient derived tumor cells or CTCs. In combination, genotypic testing provides the information to predict the effect of potent drugs from patients' genotypes. These data can be used by clinicians for the selection of drug for precise treatment therapy. Reproduced with permission from ref. ^[151] (Creative Commons Attribution 4.0 International License (CC BY 4.0)).